Clinical implication of HLA class I expression in breast cancer

Koichi Kaneko, Sumiya Ishigami, Yuko Kijima, Yawara Funasako, Munetsugu Hirata, Hiroshi Okumura, Hiroyuki Shinchi, Chihaya Koriyama, Shinichi Ueno, Heiji Yoshinaka, Shoji Natsugoe

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Background: Human leukocyte antigen (HLA)-class I molecules on tumor cells have been regarded as crucial sites where cytotoxic T lymphocytes (CTL) can recognize tumor-specific antigens and are strongly associated with anti-tumor activity. However, the clinical impact of HLA class I expression in breast cancer has not been clarified.Methods: A total of 212 breast cancer patients who received curative surgery from 1993 to 2003 were enrolled in the current study. HLA class I expression was examined immunohistochemically using an anti-HLA class I monoclonal antibody. The correlation between HLA class I positivity and clinical factors was analyzed.Results: The downregulation of HLA class I expression in breast cancer was observed in 69 patients (32.5%). HLA class I downregulation was significantly associated with nodal involvement (p < 0.05), TNM stage (p < 0.05), lymphatic invasion (p < 0.01), and venous invasion (p < 0.05). Patients with preserved HLA class I had significantly better disease-free interval (DFI) than those with loss of HLA class I (p < 0.05). However, in multivariable analysis, HLA class I was not selected as one of the independent prognostic factors of disease-free interval.Conclusion: The examination of HLA class I expression is useful for the prediction of tumor progression and recurrent risk of breast cancer via the antitumor immune system.

Original languageEnglish
Article number454
JournalBMC Cancer
Volume11
DOIs
Publication statusPublished - 20-10-2011

All Science Journal Classification (ASJC) codes

  • Genetics
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical implication of HLA class I expression in breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Kaneko, K., Ishigami, S., Kijima, Y., Funasako, Y., Hirata, M., Okumura, H., Shinchi, H., Koriyama, C., Ueno, S., Yoshinaka, H., & Natsugoe, S. (2011). Clinical implication of HLA class I expression in breast cancer. BMC Cancer, 11, [454]. https://doi.org/10.1186/1471-2407-11-454